{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:24:13Z","timestamp":1794263053203,"version":"4.9.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.pharmthera.2020.107612","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T11:28:52Z","timestamp":1592393332000},"page":"107612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Diagnosis and management of systemic light chain AL amyloidosis"],"prefix":"10.1016","volume":"214","author":[{"given":"Divaya","family":"Bhutani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.pharmthera.2020.107612_bb0005","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1182\/blood-2002-09-2707","article-title":"Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL)","volume":"101","author":"Abraham","year":"2003","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107612_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.bmt.1705395","article-title":"Multiple myeloma-associated AL amyloidosis: Is a distinctive therapeutic approach warranted?","volume":"38","author":"Bahlis","year":"2006","journal-title":"Bone Marrow Transplantation"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107612_bb0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCIMAGING.112.978627","article-title":"Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: An equilibrium contrast cardiovascular magnetic resonance study","volume":"6","author":"Banypersad","year":"2013","journal-title":"Circulation. Cardiovascular Imaging"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107612_bb0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jmb.2013.10.016","article-title":"Kinetic control in protein folding for light chain amyloidosis and the differential effects of somatic mutations","volume":"426","author":"Blancas-Mej\u00eda","year":"2014","journal-title":"Journal of Molecular Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107612_bb0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circulation. Cardiovascular Imaging"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107612_bb0030","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients with ATTR Cardiac Amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107612_bb0035","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","article-title":"Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients","volume":"91","author":"Comenzo","year":"1998","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107612_bb0040","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/bmt.2015.73","article-title":"Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation","volume":"50","author":"Cornell","year":"2015","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.pharmthera.2020.107612_bb0045","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/10428199709059685","article-title":"Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation","volume":"27","author":"Desikan","year":"1997","journal-title":"Leukemia & Lymphoma"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107612_bb0050","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1182\/blood-2012-02-413161","article-title":"Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis","volume":"119","author":"Dispenzieri","year":"2012","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107612_bb0055","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.21822","article-title":"Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs","volume":"85","author":"Dispenzieri","year":"2010","journal-title":"American Journal of Hematology"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107612_bb0060","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"Supplement_1","key":"10.1016\/j.pharmthera.2020.107612_bb0065","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood-2019-124409","article-title":"Primary results from the phase 3 tourmaline-AL1 trial of Ixazomib-dexamethasone versus Physician\u2019s choice of therapy in patients (Pts) with relapsed\/refractory primary systemic AL amyloidosis (RRAL)","volume":"134","author":"Dispenzieri","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107612_bb0070","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","article-title":"The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis","volume":"109","author":"Dispenzieri","year":"2007","journal-title":"Blood."},{"issue":"32","key":"10.1016\/j.pharmthera.2020.107612_bb0075","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A Center for International Blood and Marrow Transplant Research Study","volume":"33","author":"D\u2019Souza","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107612_bb0080","first-page":"509","article-title":"Final analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with relapsed or refractory AL amyloidosis","volume":"130","author":"Edwards","year":"2017","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.pharmthera.2020.107612_bb0085","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation."},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107612_bb0090","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"American Journal of Hematology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107612_bb0095","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2012.170","article-title":"Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis","volume":"48","author":"Gertz","year":"2013","journal-title":"Bone Marrow Transplantation"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107612_bb0100","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/cncr.30051","article-title":"Stem cell transplantation compared with Melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis","volume":"122","author":"Gertz","year":"2016","journal-title":"Cancer."},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107612_bb0105","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107612_bb0110","doi-asserted-by":"crossref","unstructured":"Gertz MA, Leung N, Lacy MQ et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrology, Dialysis, Transplantation 24(10):3132\u20133137.","DOI":"10.1093\/ndt\/gfp201"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107612_bb0115","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/bmt.2013.192","article-title":"Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement","volume":"49","author":"Girnius","year":"2014","journal-title":"Bone Marrow Transplantation"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107612_bb0120","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.kint.2019.05.027","article-title":"The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry","volume":"96","author":"Gonzalez Suarez","year":"2019","journal-title":"Kidney International"},{"key":"10.1016\/j.pharmthera.2020.107612_bb0125","first-page":"1","article-title":"Rapid complete response to single-agent Bcl-2 inhibitor Venetoclax in a heart-transplanted patient with triple refractory immunoglobulin light-chain amyloidosis","author":"Gran","year":"2020","journal-title":"Acta Haematologica"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107612_bb0140","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-12-2","article-title":"Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: A randomized controlled trial","volume":"12","author":"Huang","year":"2014","journal-title":"BMC Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107612_bb0145","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"The New England Journal of Medicine"},{"issue":"Supplement 1","key":"10.1016\/j.pharmthera.2020.107612_bb0150","first-page":"3151","article-title":"Bortezomib-maintenance for patients with AL amyloidosis: A single Center experience","volume":"130","author":"Jimenez-Zepeda","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107612_bb0155","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/bcj.2017.47","article-title":"Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib","volume":"7","author":"Kastritis","year":"2017","journal-title":"Blood Cancer Journal"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107612_bb0160","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.V128.22.646.646","article-title":"A randomized phase III trial of Melphalan and dexamethasone (MDex) versus Bortezomib, Melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis","volume":"128","author":"Kastritis","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107612_bb0165","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107612_bb0170","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107612_bb0175","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2017.1314959","article-title":"Amyloid in bone marrow smears in systemic light-chain amyloidosis","volume":"24","author":"Kimmich","year":"2017","journal-title":"Amyloid."},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107612_bb0180","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.2019003633","article-title":"Daratumumab for systemic AL amyloidosis: Prognostic factors and adverse outcome with nephrotic range albuminuria","volume":"135","author":"Kimmich","year":"2020","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107612_bb0185","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.mayocp.2017.02.016","article-title":"Presentation and outcomes of localized immunoglobulin light chain amyloidosis","volume":"92","author":"Kourelis","year":"2017","journal-title":"The Mayo Clinic Experience. Mayo Clin Proc."},{"issue":"21","key":"10.1016\/j.pharmthera.2020.107612_bb0190","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1182\/blood-2012-01-407791","article-title":"Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis:Long-term results from a phase 2 trial","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107612_bb0195","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ajh.24181","article-title":"Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma","volume":"90","author":"Kumar","year":"2015","journal-title":"American Journal of Hematology"},{"issue":"17","key":"10.1016\/j.pharmthera.2020.107612_bb0200","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107612_bb0205","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood."},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107612_bb0210","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1200\/JCO.19.01721","article-title":"Bendamustine with dexamethasone in relapsed\/refractory systemic light-chain amyloidosis: Results of a phase II study","volume":"38","author":"Lentzsch","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107612_bb0215","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"The New England Journal of Medicine"},{"issue":"26","key":"10.1016\/j.pharmthera.2020.107612_bb0220","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/blood-2013-01-453001","article-title":"Systemic light chain amyloidosis: An update for treating physicians","volume":"121","author":"Merlini","year":"2013","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107612_bb0225","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2009.01.022","article-title":"Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: A systematic review","volume":"15","author":"Mhaskar","year":"2009","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"19","key":"10.1016\/j.pharmthera.2020.107612_bb0230","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107612_bb0235","doi-asserted-by":"crossref","first-page":"H95","DOI":"10.1152\/ajpheart.00186.2013","article-title":"Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish","volume":"305","author":"Mishra","year":"2013","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107612_bb0240","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1182\/blood-2010-07-294405","article-title":"Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: A multicenter phase 1\/2 dose-escalation study","volume":"116","author":"Moreau","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.pharmthera.2020.107612_bb0245","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood.V87.7.3063.bloodjournal8773063","article-title":"High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement","volume":"87","author":"Moreau","year":"1996","journal-title":"Blood."},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107612_bb0250","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: Cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood."},{"issue":"Supplement_1","key":"10.1016\/j.pharmthera.2020.107612_bb0255","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood-2019-130307","article-title":"AL amyloidosis: The effects of maintenance therapy on autologous stem cell transplantation outcomes","volume":"134","author":"Ozga","year":"2019","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.pharmthera.2020.107612_bb0260","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107612_bb0265","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.pharmthera.2020.107612_bb0270","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: Safety run-in results of ANDROMEDA","author":"Palladini","year":"2020","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107612_bb0275","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1182\/blood-2005-11-4385","article-title":"Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL","volume":"107","author":"Palladini","year":"2006","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107612_bb0280","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107612_bb0285","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2002-01-0114","article-title":"Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment","volume":"100","author":"Perfetti","year":"2002","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107612_bb0290","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2011-05-355784","article-title":"The repertoire of \u03bb light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44","volume":"119","author":"Perfetti","year":"2012","journal-title":"Blood."},{"issue":"19","key":"10.1016\/j.pharmthera.2020.107612_bb0295","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart."},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107612_bb0300","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.clml.2019.07.003","article-title":"Venetoclax in immunoglobulin light chain amyloidosis: Is this the beginning or the end?","volume":"19","author":"Premkumar","year":"2019","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.pharmthera.2020.107612_bb0305","author":"Prothena Discontinues Development Of NEOD001 For AL Amyloidosis"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107612_bb0310","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.echo.2017.08.017","article-title":"Prognostic and added value of two-dimensional global longitudinal strain for prediction of survival in patients with light chain amyloidosis undergoing autologous hematopoietic cell transplantation","volume":"31","author":"Pun","year":"2018","journal-title":"Journal of the American Society of Echocardiography"},{"issue":"24","key":"10.1016\/j.pharmthera.2020.107612_bb0315","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"Quarta","year":"2017","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2020.107612_bb0320","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/(SICI)1097-0142(19980415)82:8<1501::AID-CNCR11>3.0.CO;2-8","article-title":"Primary systemic amyloidosis with delayed progression to multiple myeloma","volume":"82","author":"Rajkumar","year":"1998","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107612_bb0325","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107612_bb0330","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood.2019004369","article-title":"A prospective phase II of daratumumab in previously treated systemic light chain amyloidosis (AL) patients","volume":"135","author":"Roussel","year":"2020","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107612_bb0335","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation."},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107612_bb0340","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/ehjci\/jew298","article-title":"Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis","volume":"18","author":"Salinaro","year":"2017","journal-title":"European Heart Journal Cardiovascular Imaging"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107612_bb0345","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","article-title":"A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory light-chain (AL) amyloidosis","volume":"130","author":"Sanchorawala","year":"2017","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107612_bb0350","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3324\/haematol.2012.075192","article-title":"Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: Results of a phase II trial","volume":"98","author":"Sanchorawala","year":"2013","journal-title":"Haematologica."},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107612_bb0355","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2016-04-710822","article-title":"Pomalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 1 and 2 trial","volume":"128","author":"Sanchorawala","year":"2016","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107612_bb0360","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107612_bb0365","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","article-title":"Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway","volume":"107","author":"Shi","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107612_bb0370","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/13506129.2016.1257986","article-title":"Amyloid fibril proteins and amyloidosis: Chemical identification and clinical classification International Society of Amyloidosis 2016 nomenclature guidelines","volume":"23","author":"Sipe","year":"2016","journal-title":"Amyloid."},{"issue":"10 Pt 2","key":"10.1016\/j.pharmthera.2020.107612_bb0375","article-title":"Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4","volume":"9","author":"Solomon","year":"2003","journal-title":"Clinical Cancer Research"},{"issue":"19","key":"10.1016\/j.pharmthera.2020.107612_bb0380","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107612_bb0385","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry\u2013based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107612_bb0390","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3324\/haematol.2013.102764","article-title":"Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics","volume":"99","author":"Vrana","year":"2014","journal-title":"Haematologica."},{"key":"10.1016\/j.pharmthera.2020.107612_bb0395","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fimmu.2011.00032","article-title":"Generation and characterization of anti-AA amyloid-specific monoclonal antibodies","volume":"2","author":"Wall","year":"2011","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2020.107612_bb0400","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1182\/blood-2010-03-273797","article-title":"Radioimmunodetection of amyloid deposits in patients with AL amyloidosis","volume":"116","author":"Wall","year":"2010","journal-title":"Blood"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582030142X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582030142X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:06:26Z","timestamp":1759010786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372582030142X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":78,"alternative-id":["S016372582030142X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107612","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and management of systemic light chain AL amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107612","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107612"}}